INSM
Price
$152.63
Change
-$4.53 (-2.88%)
Updated
Feb 4, 02:52 PM (EDT)
Capitalization
33.52B
15 days until earnings call
Intraday BUY SELL Signals
NUVL
Price
$103.77
Change
-$3.40 (-3.17%)
Updated
Feb 4, 03:04 PM (EDT)
Capitalization
8.32B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INSM vs NUVL

Header iconINSM vs NUVL Comparison
Open Charts INSM vs NUVLBanner chart's image
Insmed
Price$152.63
Change-$4.53 (-2.88%)
Volume$100
Capitalization33.52B
Nuvalent
Price$103.77
Change-$3.40 (-3.17%)
Volume$3.1K
Capitalization8.32B
INSM vs NUVL Comparison Chart in %
INSM
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
INSM vs. NUVL commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Hold and NUVL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (INSM: $157.16 vs. NUVL: $107.17)
Brand notoriety: INSM and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INSM: 79% vs. NUVL: 66%
Market capitalization -- INSM: $33.52B vs. NUVL: $8.32B
INSM [@Biotechnology] is valued at $33.52B. NUVL’s [@Biotechnology] market capitalization is $8.32B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INSM’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • INSM’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, both INSM and NUVL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INSM’s TA Score shows that 5 TA indicator(s) are bullish while NUVL’s TA Score has 6 bullish TA indicator(s).

  • INSM’s TA Score: 5 bullish, 3 bearish.
  • NUVL’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than INSM.

Price Growth

INSM (@Biotechnology) experienced а -3.37% price change this week, while NUVL (@Biotechnology) price change was +0.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

INSM is expected to report earnings on Feb 19, 2026.

NUVL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($33.5B) has a higher market cap than NUVL($8.32B). NUVL YTD gains are higher at: 6.541 vs. INSM (-9.699). NUVL has higher annual earnings (EBITDA): -398.38M vs. INSM (-1.09B). INSM has more cash in the bank: 1.68B vs. NUVL (943M). INSM has higher revenues than NUVL: INSM (447M) vs NUVL (0).
INSMNUVLINSM / NUVL
Capitalization33.5B8.32B402%
EBITDA-1.09B-398.38M273%
Gain YTD-9.6996.541-148%
P/E RatioN/AN/A-
Revenue447M0-
Total Cash1.68B943M178%
Total Debt576MN/A-
FUNDAMENTALS RATINGS
INSM: Fundamental Ratings
INSM
OUTLOOK RATING
1..100
66
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
PROFIT vs RISK RATING
1..100
22
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
49
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
INSMNUVL
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
71%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 10 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
INSM
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
FOREX / NAMEPrice $Chg $Chg %
AUDCAD0.95N/A
N/A
Australian Dollar - Canadian Dollar
GBPNZD2.27N/A
N/A
United Kingdom Pound - New Zealand Dollar
NZDAUD0.86N/A
N/A
New Zealand Dollar - Australian Dollar
CHFGBP0.94N/A
N/A
Switzerland Franc - United Kingdom Pound
QDTE30.52-0.45
-1.45%
Roundhill Innovt-100 0DTE CovCllStratETF

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
+2.07%
THAR - INSM
74%
Closely correlated
-2.01%
NUVL - INSM
45%
Loosely correlated
+2.12%
ROIV - INSM
42%
Loosely correlated
+0.14%
AXON - INSM
40%
Loosely correlated
-1.89%
ARRY - INSM
40%
Loosely correlated
+1.71%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XNCR. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+2.12%
XNCR - NUVL
61%
Loosely correlated
-0.99%
CGON - NUVL
60%
Loosely correlated
-3.28%
RVMD - NUVL
59%
Loosely correlated
-1.22%
IDYA - NUVL
58%
Loosely correlated
+0.50%
XENE - NUVL
58%
Loosely correlated
+1.62%
More